A message from our Chairman, Robert Farrell
March 2, 2022 Dear Investors, Claritas has an extraordinary pharmaceutical asset in R-107, and our goal is to realize its value in the shortest possible time. We will make significant strides toward achieving that goal this year. The R-107 Back Story: The history of R-107 begins with Dr. Andrew Salzman. R-107 is a nitric oxide-releasing.
“I am often asked why we are focusing on nitric oxide as a treatment for coronavirus. The answer is simple: because we know it works.”